Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
复制标题
DOI：
10.1161/01.cir.0000133317.49796.0e
复制
发表时间：
2004-07-13
期刊：
影响因子：
37.8
通讯作者：
Stone, NJ
中科院分区：
文献类型：
--
作者：
Grundy, SM;Cleeman, JI;Stone, NJ
国家胆固醇教育计划的成人治疗小组III（ATP III）于2001年发布了一套基于证据的胆固醇管理指南。自ATP III发表以来，已发表了5项具有临床终点的他汀类药物治疗的主要临床试验。这些试验解决了以前的降胆固醇治疗临床试验中没有检查的问题。本文件回顾了这些最近的试验结果，并评估其对胆固醇管理的影响。治疗性生活方式改变（TLC）仍然是临床管理中的一种重要方式。这些试验证实了降低胆固醇治疗在高危患者中的益处，并支持ATP III治疗目标低密度脂蛋白胆固醇（LDL-C）
The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the publication of ATP III, 5 major clinical trials of statin therapy with clinical end points have been published. These trials addressed issues that were not examined in previous clinical trials of cholesterol-lowering therapy. The present document reviews the results of these recent trials and assesses their implications for cholesterol management. Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C)